Literature DB >> 2649397

Monoclonal antibody and cytological detection of free malignant cells in the peritoneal cavity during resection of colorectal cancer--can monoclonal antibodies do better?

N S Ambrose1, F MacDonald, J Young, H Thompson, M R Keighley.   

Abstract

Detection of free malignant cells in the peritoneal cavity following curative resections of colorectal cancer may explain why some patients develop local or peritoneal recurrence after favourable operations. We have examined the incidence of peritoneal malignant cells using standard cytological methods and by indirect immunoperoxidase staining using monoclonal antibodies (CEA L11/285/14 and HMFG 1 and 2) in 30 patients having resection for colorectal cancer. Peritoneal washings were collected on opening the peritoneal cavity and immediately prior to closing the abdominal wall following resection. Abnormal cells were only demonstrated in 10 patients. Cytology revealed abnormal cells in seven patients (three preresection and three postresection, one patient had pre- and postresection positive cytology). Monoclonal antibody staining revealed abnormal cells in seven patients (two preresection and four postresection, one patient had both pre- and postresection positive stains). Only two patients had identical results using cytology and antibody staining. Seven of these 10 patients had hepatic metastases. The correlation between the assessment of free malignant cells using cytology and monoclonal antibody staining is poor. Long-term follow-up is required to see if 'free cells' have prognostic significance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2649397

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  8 in total

Review 1.  [Minimal residual tumor in gastrointestinal carcinoma. Relevance to prognosis and oncologic surgical consequences].

Authors:  S Gretschel; A Bembenek; T Schulze; W Kemmner; P M Schlag
Journal:  Chirurg       Date:  2006-12       Impact factor: 0.955

2.  Impact of positive intraabdominal lavage cytology on the long-term prognosis of colorectal cancer patients.

Authors:  Rita Temesi; László Sikorszki; János Bezsilla; Akos Botos; Judit Kovács; Tibor Tihanyi
Journal:  World J Surg       Date:  2012-11       Impact factor: 3.352

Review 3.  pTNM and residual tumor classifications: problems of assessment and prognostic significance.

Authors:  P Hermanek
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

4.  [Tumor cell dissemination in bone marrow and peritoneal cavity. An immunocytochemical study of patients with stomach or colorectal carcinoma].

Authors:  R Broll; K Lembcke; C Stock; M Zingler; M Duchrow; H Schimmelpenning; M Strik; G Muller; P Kujath; H P Bruch
Journal:  Langenbecks Arch Chir       Date:  1996

5.  Use of ascitic CEA levels as a predictive value for distant metastasis in high-risk stage II and III colorectal cancer.

Authors:  Abdullah Al-Sawat; Jung Hoon Bea; Seung-Rim Han; Hyo Jin Lee; Mi Ran Yoon; Yoon Suk Lee; Do Sang Lee; Chul Seung Lee; In Kyu Lee
Journal:  Int J Colorectal Dis       Date:  2021-11-30       Impact factor: 2.571

6.  Serosal imprint cytology in colonic cancer: a simple staging technique.

Authors:  P D Murphy; J Hoffman; C Karczenski; E L Gilliland; A L Peel; T I Rosenberg
Journal:  Int J Colorectal Dis       Date:  1994-05       Impact factor: 2.571

7.  Port-site recurrence reproduced in the VX-2 rabbit carcinoma model: an in vivo model comparing laparoscopic port sites and open incisions.

Authors:  N W Wilkinson; A J Shapiro; S B Harvey; R S Stack; R L Cornum
Journal:  JSLS       Date:  2001 Jul-Sep       Impact factor: 2.172

8.  Peritoneal expression of Matrilysin helps identify early post-operative recurrence of colorectal cancer.

Authors:  Giuseppe S Sica; Cristina Fiorani; Carmine Stolfi; Giovanni Monteleone; Eleonora Candi; Ivano Amelio; Valeria Catani; Simone Sibio; Andrea Divizia; Giorgia Tema; Edoardo Iaculli; Achille L Gaspari
Journal:  Oncotarget       Date:  2015-05-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.